Regulatory Affairs Associates

Regulatory Affairs Associates

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Regulatory Affairs Associates is a long-established, privately-held consulting firm providing specialized regulatory affairs services to the healthcare product industry. Its core business is offering expert guidance to navigate the U.S. FDA and international regulatory pathways for drugs, medical devices, and supplements. The company's value proposition is built on decades of experience, a results-oriented process, and a team with deep institutional knowledge, having facilitated the creation of hundreds of companies and thousands of jobs. RAA operates as a service provider, generating revenue through client consulting engagements, and positions itself as an essential partner for innovators seeking to bring new healthcare technologies to market.

Digital Health

Technology Platform

Accumulated regulatory intellectual capital and expert consulting methodologies for FDA and international health authority submissions.

Opportunities

Growing complexity in regulatory pathways for novel therapies (e.g., cell/gene, digital health) and the continuous formation of startup biotech/device companies create sustained demand for expert consulting.
Expansion of services into high-growth areas like AI/ML-based software as a medical device (SaMD) and international market access presents significant growth potential.

Risk Factors

Revenue is highly dependent on the funding cycle and R&D spending of client companies, creating cyclical vulnerability.
The firm's value is concentrated in its key personnel, creating talent retention and succession risks.
Intense competition from both large global CROs and niche boutique firms pressures margins and client acquisition.

Competitive Landscape

RAA competes in a fragmented market including large, full-service Contract Research Organizations (CROs) with regulatory divisions and numerous small-to-midsize specialized regulatory consulting firms. Its differentiation is based on deep, founder-led expertise, a long track record, and a boutique focus on strategic regulatory guidance rather than broad clinical trial execution.